Moderna Tops Large-Cap Healthcare Stocks Moderna shares rose ~38% YTD through Mar 24, 2026, making it the top large-cap healthcare performer; market cap near $112bn and XLV was +6% YTD (Seeking Alpha; Yahoo Finance; Bloomberg).

Moderna Tops Large-Cap Healthcare Stocks: Moderna shares rose ~38% YTD through Mar 24, 2026, making it the top large-cap healthcare performer; market cap near $112bn and XLV was +6% YTD (Seeking Alpha; Yahoo… 👈 Read full analysis #Moderna #HealthcareStocks #Investing #StockMarket #HealthTech

Health insurers like $MOH (-25.51%) and $CNC (-3.66%) saw significant drops as rising Medicaid costs outstrip payments. Profitability in this sector faces mounting pressure. 📉🏥 #HealthcareStocks #Medicaid

Healthcare insurers like $HUM and $UNH saw sharp declines as Medicare rates are likely to remain flat in 2027. This poses challenges for revenue growth in the sector. 📉 #HealthcareStocks #MarketAnalysis

We recently initiated coverage on Cosmos Health Inc., a vertically integrated healthcare company spanning pharma, nutraceuticals, distribution, and technology-enabled services. #COSM #HealthcareStocks #SmallCaps

youtu.be/MlV2cvg4QXg

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 Eli Lilly (LLY) shows strong momentum in weight management, diabetes treatments and pipeline drugs l...

Eli Lilly (LLY) shows strong momentum in weight management, diabetes treatments and pipeline drugs like orforglipron and retatrutide. Analysts project almost $62B in sales by 2030. #HealthcareStocks #News

Milestone: Eli Lilly [finance:Eli Lilly and Company] hits $1 trillion market cap—a first for health care! 💊🚀 #EliLilly #HealthcareStocks #MarketNews #CNBC #BlueSky

Premier shares surge on report Patient Square Capital is exploring acquisition Investing.com -- Premier Inc shares rose over 8% in premarket trading Monday following a Bloomberg News report that Patient Square Capital is exploring an acquisition of the health-care services company. The report, published Friday, cited people familiar with the matter who indicated that deliberations between the parties are still at an early stage. There is no guarantee that these discussions will result in a deal with Patient Square Capital or any other potential buyer. Leerink Partners analyst Michael Cherny commented on the news in a note, stating, "Given that Premier has already attempted one sale process, seeing another one crop up cannot be considered shocking by any means." Cherny added, "We see a reasonable basis as to why PINC would explore a transaction, as to us this has always seemed to be a better business than is reflected in the stock." The analyst noted that Premier’s stock should react favorably to the news. Premier has had a solid year of performance but remains "somewhat of an outlier as the only publicly traded GPO," according to Cherny. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Get an up-to-the-minute summary from WarrenAI, our powerful AI financial researcher. It's just like ChatGPT for investors, but with access to 1,200+ premium metrics spanning 10 years of data to instantly screen fundamentals, summarize breaking news, and reveal what Wall Street analysts are really saying about PINC. Ask questions in your own language and get insider answers in seconds. Think of it as your experienced investment partner—always ready to help you think through every angle of PINC.

Click Subscribe #PremierInc #PatientSquareCapital #Acquisition #InvestingNews #HealthcareStocks

Healthcare Stocks Are Just Starting Their Resurgence. Hold On to Them. - Barron's Healthcare Stocks Are Just Starting Their Resurgence. Hold On to Them.  Barron's

Click Subscribe #HealthcareStocks #Investing #StockMarket #HealthTech #MarketTrends

Click Subscribe #SwedenStocks #OMXStockholm30 #StockMarket #Investing #HealthcareStocks

UBS downgrades Fresenius Medical Care to “sell,” warns on U.S. dialysis outlook Investing.com -- Fresenius Medical Care AG (ETR:FMEG) was downgraded to “sell” from “neutral” by UBS, which cut its price target to €38 from €43.50, citing both near-term earnings headwinds and longer-term structural risks in the U.S. dialysis market, in a note dated Tuesday. The German healthcare company was trading lower at 4.8% at 04:46 ET (08:46 GMT). Shares closed at €43.79 on Aug. 29, leaving what analysts described as more than 10% downside risk. UBS said Fresenius had staged a sharp turnaround under CEO Helen Giza, who took over in 2022 during a period marked by inflation and staffing pressures. Earnings upgrades and margin recovery helped the stock nearly double to about €50 earlier this year, outperforming the broader European MedTech sector by roughly 50%. But the brokerage warned that momentum has stalled, with consensus estimates for 2025 and 2026 looking too optimistic. The downgrade rests on structural concerns about dialysis volumes in the United States, the company’s largest market. UBS noted that new therapies for chronic kidney disease, including GLP-1s and other drug classes, are slowing disease progression, reducing the number of patients entering dialysis. At the same time, the dialysis population is aging, pushing up mortality rates. Even with the rollout of high-volume hemodiafiltration, which can improve outcomes for some patients, UBS expects U.S. volume growth to peak at 1.5% before turning negative after 2030. That compares unfavorably with consensus models that assume steady growth. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Financially, UBS trimmed its forecasts to reflect weaker volumes, foreign exchange headwinds, and rising costs tied to new technology. Revenue is expected to be broadly flat at €19.4 billion in 2025 before gradually rising to €22 billion by 2028. Adjusted EBIT is projected to improve from €1.8 billion in 2024 to €2.6 billion in 2028, with margins climbing from 9.3% to 11.7% over the same period. Earnings per share are seen at €3.43 in 2025, rising to €4.96 in 2028. Dividends are projected to increase from €1.20 in 2025 to €1.74 in 2028, implying a yield close to 4%. Despite those improvements, UBS cautioned that the shares’ valuation does not leave much upside. Fresenius trades at about 13 times forward 2025 earnings, in line with the sector’s two- to three-year average discount. The brokerage’s HOLT analysis found that cash flow returns on investment have fallen from around 15% in 2012 to 3.7% in 2024, while earnings quality has slipped relative to peers. UBS said sustaining the current share price would require a significant uplift in returns, which it views as unlikely now that most of the margin recovery has already been delivered. Should you invest $2,000 in FMEG right now? First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens, both up over 60%+ each in Q2 of 2025 alone. Is FMEG one of them?

Click Subscribe #FreseniusMedicalCare #UBSDowngrade #DialysisMarket #HealthcareStocks #InvestingNews

2 Healthcare Stocks on Our Watchlist and 1 We Avoid - Yahoo Finance 2 Healthcare Stocks on Our Watchlist and 1 We Avoid  Yahoo Finance

Click Subscribe #HealthcareStocks #Investing #StockMarket #Finance #Healthcare

Healthcare Stocks Are ‘Priced at Panic Levels.’ It’s Time to Buy. - Barron's Healthcare Stocks Are ‘Priced at Panic Levels.’ It’s Time to Buy.  Barron's

Click Subscribe #HealthcareStocks #Investing #StockMarket #PanicSelling #FinancialNews

🚀 Exciting times for #APM! With DiamiR's APOE test approval boosting market position pre-merger, Aptorum Group is on the rise. Consider a long position at $1.80, targeting $2.20 & $2.50. Stay alert to market trends and merger news! 📈 #HealthcareStocks #FeetrAI

Pop Mart, Health-Care Stocks Lead Hang Seng Index Contenders - Bloomberg.com Pop Mart, Health-Care Stocks Lead Hang Seng Index Contenders  Bloomberg.com

Click Subscribe #PopMart #HealthCareStocks #HangSengIndex #BloombergNews #StockMarket

Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started. - Barron's Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.  Barron's

Click Subscribe #HealthcareStocks #Investing #StockMarket #FinancialNews #MarketTrends

Why UnitedHealth Stock Pushed Higher on Monday - Nasdaq Why UnitedHealth Stock Pushed Higher on Monday  Nasdaq

Click Subscribe #UnitedHealth #StockMarket #Investing #FinanceNews #HealthCareStocks

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - The Motley Fool Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm  The Motley Fool

Click Subscribe #Pharmaceuticals #StockMarket #Investing #FinanceNews #HealthcareStocks

Eli Lilly and health-care stocks are week's big winners, 3 sectors in the red - CNBC Eli Lilly and health-care stocks are week's big winners, 3 sectors in the red  CNBC

Click Subscribe #EliLilly #HealthcareStocks #StockMarket #Investing #FinancialNews

Why Is UnitedHealth Stock Trading Higher Friday? - Yahoo Finance Why Is UnitedHealth Stock Trading Higher Friday?  Yahoo Finance

Click Subscribe #UnitedHealth #StockMarket #Investing #FinanceNews #HealthCareStocks

Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? - Zacks Investment Research Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?  Zacks Investment Research

Click Subscribe #EliLilly #HealthcareStocks #Investing #StockMarket #Finance

Medical, Gold, Aerospace Stocks Join Best Stocks Lists: Check Out IBD 50, The Big Cap 20, Stock Spotlight And Others - Investor's Business Daily Medical, Gold, Aerospace Stocks Join Best Stocks Lists: Check Out IBD 50, The Big Cap 20, Stock Spotlight And Others  Investor's Business Daily

Click Subscribe #Investing #StockMarket #Aerospace #GoldStocks #HealthcareStocks

European shares end flat as healthcare stocks weigh after Trump's tariff threat - Reuters European shares end flat as healthcare stocks weigh after Trump's tariff threat  Reuters

Click Subscribe #EuropeanShares #HealthcareStocks #TariffThreat #StockMarket #FinancialNews

CVS Health Q2: revenue up 8.4% to $98.9B, adjusted EPS $1.81 vs $1.46 est. Full-year EPS guidance raised.

Read more 👉 buff.ly/oTTKn8Q

#CVS #Earnings #HealthcareStocks

----
Disclaimer: Info only. DYOR. buff.ly/tNWBvJD

3 Healthcare Stocks Paying the Highest Dividends of 2025 - The Motley Fool 3 Healthcare Stocks Paying the Highest Dividends of 2025  The Motley Fool

Click Subscribe #HealthcareStocks #Dividends2025 #Investing #StockMarket #FinancialNews

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run - Yahoo Finance 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run  Yahoo Finance

Click Subscribe #HealthcareStocks #Investing #StockMarket #FinanceNews #InvestmentTips

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run - Nasdaq 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run  Nasdaq

Click Subscribe #HealthcareStocks #StockMarket #Investing #Finance #InvestmentStrategy

European shares slide to 3-week lows as healthcare stocks hit; new US tariffs in focus August 1 (Reuters) -European stocks hit a 3-week low on Friday at the end of a busy week as investors worried about the impact of fresh U.S. levies on dozens of countries including a 39% rate on Switzerland. On the day, healthcare stocks dropped 1.3% after U.S. President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies including Novo Nordisk (NYSE:NVO) and Sanofi (NASDAQ:SNY) outlining how they should slash U.S. prescription drug prices. Novo Nordisk shed 4.2%, falling to an almost three-year low, while Sanofi shed 1%. The pan-European STOXX 600 index fell almost 1% by 0720 GMT, down for the third straight session and on track to end the week in red. The benchmark index has slipped 4.4% from its Monday peak, when it came within 1.8% of its March all-time high, dragged down by a record plunge in Novo Nordisk shares following a profit warning, and as investors assessed the implications of the U.S.-EU trade deal. Trump continued his tariff blitz, announcing steep levies on exports from dozens of trading partners including Canada, Brazil, India and Taiwan with countries not listed subject to a base 10% rate ahead of a Friday trade deal deadline. Germany blue-chip DAX shed 1.1% while Denmark’s OMXC fell 2.8% to a nearly two-year low. Most regional bourses were in the red. Among individual stocks, Italy’s Campari (LON:0ROY) was the top gainer on the STOXX 600 index, adding 8.6% after reporting an increase in second-quarter operating profit. British Airways owner IAG gained 2.1% after reporting better-than-expected quarterly earnings on continued demand for transatlantic routes.

Click Subscribe #EuropeanStocks #HealthcareStocks #USTariffs #StockMarketNews #Investing

Fitch revises UnitedHealth’s outlook to negative amid profit pressure Investing.com -- Fitch Ratings has revised UnitedHealth Group (NYSE:UNH)’s outlook to negative from stable while affirming the insurer financial strength ratings of its subsidiaries at ’AA-’. The rating agency maintained UnitedHealth’s long-term issuer default rating and senior unsecured notes at ’A’, along with United HealthCare Services, Inc.’s issuer default rating at ’A’. The outlook change follows UnitedHealth’s second quarter earnings call on Tuesday, where the company provided guidance indicating significantly reduced operating performance for the remainder of 2025. This performance decline suggests the company will meet its financial leverage downgrade sensitivities for the year, with only a partial recovery expected in 2026. Fitch cited weakened operating performance as a key rating driver, noting that UnitedHealth’s financial performance was "very strong until 2025." The company now faces pressure on operating margins and profitability due to unexpectedly high healthcare costs, driven by elevated utilization and unit costs. Fitch estimates the operating EBITDA margin will be approximately 6.5% in 2025, down from 9.8% in 2024. The rating agency also highlighted pressure on capitalization and leverage metrics, which are likely to remain above guidelines for the current rating category in 2025 and possibly into 2026. Fitch estimates debt/EBITDA will reach approximately 2.7x in 2025, up from about 2.0x in 2024, while the financial leverage ratio will be approximately 43% at year-end. UnitedHealth, the largest U.S. health insurer and health services provider by total medical membership, faces several emerging headwinds that may challenge its margin recovery efforts. These include ongoing elevated healthcare utilization trends, potentially higher acuity in the Medicaid risk pool, and the likely expiration of enhanced Premium Tax Credits for Affordable Care Act individual exchange business. The company is also facing a Department of Justice investigation into aspects of its participation in the Medicare Advantage program, which Fitch views as an "event risk" with an unpredictable outcome. For the outlook to return to stable, UnitedHealth would need to show material improvement of its financial leverage ratio and debt/EBITDA ratio toward 40% and 2.0x, respectively. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in UNH, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is UNH one of them?

Click Subscribe #UnitedHealth #FitchRatings #ProfitPressure #StockMarket #HealthcareStocks

Click Subscribe #Adaptimmune #StockMarket #Investing #HealthcareStocks #CellTherapy

2 Healthcare Stocks That Are Losing to the S&P 500 This Year - The Motley Fool 2 Healthcare Stocks That Are Losing to the S&P 500 This Year  The Motley Fool

Click Subscribe #HealthcareStocks #Investing #StockMarket #Healthcare #SP500